(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 June 2008 (05.06.2008)

PCT

(10) International Publication Number
WO 2008/067280 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2007/085579

(22) International Filing Date:
27 November 2007 (27.11.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/867,448	28 November 2006 (28.11.2006)	US
60/891,088	22 February 2007 (22.02.2007)	US

(71) Applicants *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). **DANA-FARBER CANCER INSTITUTE, INC.** [US/US]; 44 Binney Street, Boston, Massachusetts 02115 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GRIFFIN, James Douglas** [US/US]; 156 Dean Road, Brookline, Massachusetts 02445 (US). **ZAWEL, Leigh** [US/US]; 13 Patriots Way, Hingham, Massachusetts 02043 (US).

(74) Agent: **MC NALLY, Lydia T.**; Novartis, Corporate Intellectual Property, One Health Plaza, East Hanover, New Jersey 07936 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

WO 2008/067280 A2

(54) Title: COMBINATION OF IAP INHIBITORS AND FLT3 INHIBITORS

(57) Abstract: The present invention relates to combinations of IAP inhibitors and FLT3 inhibitors, pharmacological compositions comprising said combination, methods of treating hematological malignancies, including acute myeloid leukemia (AML), comprising the combination of a compound that inhibits the binding of the second mitochondria-derived activator of caspase (Smac) protein to inhibitor of apoptosis (IAPs) (IAP inhibitor) and one or more pharmaceutically active agents and the use of these combinations for the treatment of acute myeloid leukemia; and a commercial package comprising said combination.